NeoGenomics, Inc. (NASDAQ:NEO) Director Bruce K. Crowther sold 20,734 shares of the company’s stock in a transaction that occurred on Tuesday, June 8th. The shares were sold at an average price of $41.46, for a total value of $859,631.64. Following the sale, the director now directly owns 59,564 shares of the company’s stock, valued at $2,469,523.44. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
NEO opened at $42.87 on Friday. The firm has a market cap of $5.06 billion, a PE ratio of -535.88 and a beta of 0.69. The company has a current ratio of 13.91, a quick ratio of 13.60 and a debt-to-equity ratio of 0.63. The stock has a 50 day moving average price of $44.17. NeoGenomics, Inc. has a 1-year low of $25.67 and a 1-year high of $61.57.
NeoGenomics (NASDAQ:NEO) last released its quarterly earnings results on Wednesday, May 5th. The medical research company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.05). The firm had revenue of $115.30 million during the quarter, compared to analyst estimates of $112.17 million. NeoGenomics had a positive return on equity of 0.83% and a negative net margin of 2.42%. The business’s revenue was up 8.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.07) EPS. As a group, equities analysts expect that NeoGenomics, Inc. will post -0.33 earnings per share for the current fiscal year.
Several equities analysts have issued reports on NEO shares. The Goldman Sachs Group started coverage on NeoGenomics in a research report on Thursday, June 3rd. They set a “buy” rating and a $55.00 target price on the stock. Raymond James reiterated a “market perform” rating on shares of NeoGenomics in a research report on Wednesday, March 3rd. Craig Hallum boosted their target price on NeoGenomics from $50.00 to $65.00 and gave the stock a “buy” rating in a research report on Thursday, February 25th. Morgan Stanley boosted their target price on NeoGenomics from $46.00 to $64.00 and gave the stock an “overweight” rating in a research report on Thursday, February 25th. Finally, Zacks Investment Research cut NeoGenomics from a “hold” rating to a “sell” rating in a research report on Wednesday, April 28th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $50.46.
NeoGenomics Company Profile
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates in two segments, Clinical Services and Pharma Services. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains.
Featured Story: Do closed-end mutual funds pay dividends?
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.